Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

83.34EUR
6:30am EST
Change (% chg)

€-0.18 (-0.22%)
Prev Close
€83.52
Open
€84.16
Day's High
€84.24
Day's Low
€83.14
Volume
83,065
Avg. Vol
558,581
52-wk High
€115.20
52-wk Low
€80.92

Chart for

About

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnol... (more)

Overall

Beta: 1.00
Market Cap(Mil.): €10,794.31
Shares Outstanding(Mil.): 129.24
Dividend: 1.20
Yield (%): 1.44

Financials

  Industry Sector
P/E (TTM): -- 32.03 17.27
EPS (TTM): -- -- --
ROI: -- 14.00 35.43
ROE: -- 15.34 17.10

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

FRANKFURT Merck KGaA and Pfizer received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies.

Feb 15 2018

UPDATE 1-Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

* Merck still sees potential against lung cancer for Bavencio (Adds trial details, background on immunotherapies)

Feb 15 2018

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

FRANKFURT, Feb 15 Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.

Feb 15 2018

Exclusive: Merck's consumer health sale at risk as Nestle bows out - sources

LONDON/FRANKFURT The sale of Merck KGaA's consumer health unit has been thrown off track after Nestle has pulled out, leaving the race to buy the maker of Seven Seas vitamins without its main contender, sources familiar with the matter told Reuters.

Feb 02 2018

Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom

PARIS/LONDON French drugmaker Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), beating Novo Nordisk and marking its second big deal this month after buying Bioverativ. | Video

Jan 29 2018

BRIEF-Forty Seven Says Agreement With Merck KGAA To Conduct Clinical Trials For Patients With Ovarian Cancer

* FORTY SEVEN - AGREEMENT WITH MERCK KGAA TO CONDUCT PHASE 1B CLINICAL TRIAL COMBINING HU5F9-G4 WITH AVELUMAB IN PATIENTS WITH OVARIAN CANCER Source text for Eikon: Further company coverage:

Jan 11 2018

Nestle frontrunner for Merck KGaA's consumer health business: Bloomberg

ZURICH Nestle is the frontrunner to buy Merck KGaA's consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting unidentified sources familiar with the matter.

Jan 10 2018

Nestle frontrunner for Merck KGaA's consumer health business - Bloomberg

ZURICH, Jan 10 Nestle is the frontrunner to buy Merck KGaA's consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting unidentified sources familiar with the matter.

Jan 10 2018

BRIEF-Juniper Pharmaceuticals Announces ‍Extension Of Supply Agreement For Crinone

* JUNIPER PHARMACEUTICALS ANNOUNCES 4.5-YEAR EXTENSION THROUGH 2024 OF CRINONE® SUPPLY AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY

Jan 08 2018

BRIEF-HTG Molecular Diagnostics Expands Its Collaboration With Merck

* HTG MOLECULAR DIAGNOSTICS EXPANDS ITS COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY

Dec 26 2017

Earnings vs. Estimates